The Column Group — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
NGM Bio is a biopharmaceutical company developing NGM120, a GDF15/GFRAL antagonist antibody, to treat conditions rooted in overactivation of the GDF15 pathway.
BiotechHealthtechSouth San Francisco, US
Diana Peng Bockus(Executive Officer, Director)
BoardRoger M. Perlmutter(Director)
Board seatPeter SvennilsonTim Kutzkey· per SEC Form D
Co-investorsRho Ventures
Nura Bio is a biotech company developing therapies for neurological disorders by targeting pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
BiotechDeep TechHealthtech
Co-investorsSamsara BioCapitalSanofi Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.